You can buy or sell TRIL and other stocks, options, ETFs, and crypto commission-free!
Trillium Therapeutics Inc. Common Shares, also called Trillium Therapeutics, is a clinical stage immuno-oncology company, which engages in the development of innovative therapies for the treatment of cancer. Read More Its pipeline is comprised of TTI-621, TTI-622, and TTI-2341(EGFR Inhibitor). The company was founded on March 31, 2004 and is headquartered in Toronto, Canada.
52 Week High
52 Week Low
Simply Wall StMar 8
The Trillium Therapeutics (TSE:TRIL) Share Price Is Down 95% So Some Shareholders Are Rather Upset
Long term investing works well, but it doesn’t always work for each individual stock. We really hate to see fellow investors lose their hard-earned money. Spare a thought for those who held Trillium Therapeutics Inc. (TSE:TRIL) for five whole years – as the share price tanked 95%. And it’s not just long term holders hurting, because the stock is down 90% in the last year. Shareholders have had an even rougher run lately, with the share price down 67% in the last 90 days. We really hope anyone holding throu...
Markets InsiderFeb 22
Trillium Announces Pricing of US$15 Million Public Offering of Common Share Units and Series II Non-Voting Convertible First Preferred Share Units
TORONTO, Feb. 22, 2019 (GLOBE NEWSWIRE) -- Trillium Therapeutics Inc. (“Trillium” or the “Company”) (NASDAQ/TSX: TRIL), a clinical stage immuno-oncology company developing innovative therapies for the treatment of cancer, today announced that it has priced its previously announced underwritten public offering of 6,550,000 common share units (the “Common Share Units”) of the Company and 12,200,000 Series II Non-Voting Convertible First Preferred Share units (the “Series II First Preferred Share Units”) of th...
Available Mar 11, After Hours